Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Abera Bioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Orexo Announces Positive Data for Powder-based Intranasal Vaccine
Details : Abera's influenza vaccine candidate is administered intranasally, either formulated as a liquid nasal solution or as an intranasal powder using Orexo's AmorphOX technology.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 10, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Abera Bioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ebselen,Silver Ions
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Mikael Lonn
Deal Size : $2.4 million
Deal Type : Series A Financing
TXN Systems Raises SEK 25 Million Series A to Advance First-in-Class Antibiotic
Details : The financing will support the development of EbsArgent, the company's first-in-class bactericidal antibiotic for urinary tract infections (UTIs) caused by antibiotic-resistant bacteria.
Product Name : EbsArgent
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 30, 2024
Lead Product(s) : Ebselen,Silver Ions
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Mikael Lonn
Deal Size : $2.4 million
Deal Type : Series A Financing
Lead Product(s) : mRNA-Based HSV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Outstanding Results for Eurocine Vaccines´ mRNA Based HSV-2 Candidate
Details : Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T cell and antibody responses.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 20, 2022
Lead Product(s) : mRNA-Based HSV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LMW-Dextran Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African and Asian) and Yellow Fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral particles.
Product Name : ILB
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2022
Lead Product(s) : LMW-Dextran Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : ISR
Deal Size : $10.3 million
Deal Type : Agreement
ISR Signs Agreement with Iconovo for Development of Inhaled Covid-19 Vaccine
Details : ISR will have exclusive rights to use ICOone for treating Covid-19 and its variants with a technology based on spike proteins with an adjuvant. Iconovo will develop an inhalation product for the purpose of testing it in a human clinical trial.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 04, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : ISR
Deal Size : $10.3 million
Deal Type : Agreement
Lead Product(s) : Tafoxiparin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Liverpool University
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Liverpool University with Keele University will study Tafoxiparin in order to find an effective treatment of patients who’ve been struck by COVID-19 virus.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 17, 2020
Lead Product(s) : Tafoxiparin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Liverpool University
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Corona Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ISR Starts Vaccine Development For Coronavirus
Details : The vaccine is based on TCER AB's platform technology for the production of proteins and ISR's drug pipeline with immunostimulating immunolides.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 19, 2020
Lead Product(s) : Corona Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable